08:22 AM EST, 11/25/2024 (MT Newswires) -- Biohaven ( BHVN ) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a "statistically significant difference" compared with placebo and standard of care at 48 weeks.

The company said the experimental treatment "showed clinically meaningful improvements" in motor function for patients in the study.

Biohaven ( BHVN ) said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.

Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.